Novocure Ltd Stock
Price
Target price
€21.34
€21.34
4.840%
1.0
4.840%
-
24.05.24 / Tradegate
WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Novocure Ltd Stock
Novocure Ltd dominated the market today, gaining €1.00 (4.840%).
Our community identified positive and negative aspects for Novocure Ltd stock for the coming years. 1 users see the criterium "Shareholder structure" as a plus for the Novocure Ltd stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Novocure Ltd in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novocure Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | 4.840% | 5.435% | 89.436% | -71.271% | 49.492% | -85.644% | - |
| Ironwood Pharmaceuticals | -7.500% | -4.310% | -25.503% | -44.221% | -45.588% | -45.050% | - |
| Iovance Biotherapeutics Inc. | -2.500% | -2.040% | -15.627% | 22.927% | 18.110% | -36.836% | - |
| Fibrogen Inc. | 3.660% | 4.974% | 20.880% | -92.574% | 39.884% | -93.080% | - |
News
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the
Novocure Reports First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The